Nasdaq
$40.13▼ 1.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.33BShares out 58.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 3d agoPre-market26.10.22 10:07filed8-KKey event#●●●#●●●
SUPERNUS PHARMACEUTICALS, INC.Bullish
Supernus Pharmaceuticals has received seven years of orphan-drug market exclusivity from the FDA for its Parkinson's disease treatment, ONAPGO. Additionally, the company has submitted a supplemental New Drug Application (sNDA) for a second supplier for ONAPGO, with potential approval expected by mid-year 2027.…more
$40.13-1.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 05:518-KKey event
SUPERNUS PHARMACEUTICALS, INC.
Supernus Pharmaceuticals announced that it will report its financial and business results for the third quarter of 2026 after the market closes on October 29, 2026. Management will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the quarterly results.…more
$40.13-1.30%vs prev closeView filingShare - 10.15After-hours26.10.16 05:108-KKey event
SUPERNUS PHARMACEUTICALS, INC.
Supernus Pharmaceuticals held a special meeting of stockholders on October 15, 2026, and approved the merger agreement with Indivior Pharmaceuticals, Inc. Upon completion of the merger, Supernus will become a wholly-owned subsidiary of Indivior.…more
$40.13-1.30%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 06:23
S&P SmallCap 600 Index Rebalancing Announced
S&P Dow Jones Indices announced that MSG Rangers and Huron Consulting Group will join the S&P SmallCap 600. Arbor Realty Trust and Supernus Pharmaceuticals will be removed from the index as part of the rebalancing.…more
$40.13-1.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoOvernight26.10.22 16:44
●●●●●●●● ●●●●● ●●●●●●
Supernus has been granted seven years of market exclusivity for its drug ONAPGO under FDA orphan-drug status. The company has also submitted an sNDA to add a second supplier, with approval expected by mid-2027.…more
$40.13-1.30%vs prev closeShareBenzinga - 3d agoAfter-hours26.10.22 08:45
●●●●●●●● ●●●●● ●●●●●●
Supernus Pharmaceuticals has been granted seven years of orphan drug exclusivity for its Parkinson's disease treatment, ONAPGO. The company also submitted a supplemental New Drug Application to the FDA to add a second supplier for the product.…more
$40.13-1.30%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report